Aoxin Receives In-Principle Approval From SGX-ST
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Metsä Board Swings to Q3 Comparable Operating Profit of EUR 5.5 Million
Metsä Board reported a comparable operating profit of EUR 5.5 million for Q3 2026, versus a loss a year earlier.
M impact | EQUITY | Oct 29, 2026, 10:16 AM UTC
Bunge Global Q3 Revenue USD 23.804 Billion vs. IBES Estimate USD 23.169 Billion
Bunge Global reported Q3 revenue of USD 23,804 million, compared with the IBES estimate of USD 23,169 million.
M impact | EQUITY | Oct 29, 2026, 10:06 AM UTC
L3Harris Reports $19.3B in Third-Quarter Orders
L3Harris Technologies reported third-quarter orders of $19.3 billion and a book-to-bill ratio of 3.2x.
M impact | EQUITY | Oct 29, 2026, 10:06 AM UTC
AbbVie Says Qulipta Outperformed Topiramate in Phase 3 Trial
AbbVie reported that Qulipta outperformed topiramate in a Phase 3 migraine prevention trial.
L impact | EQUITY | Oct 29, 2026, 10:06 AM UTC
L3Harris Q3 Revenue Reaches $6.1 Billion, Above Estimate
L3Harris reported Q3 revenue of $6.1 billion, versus an IBES estimate of $5.913 billion.
M impact | EQUITY | Oct 29, 2026, 10:05 AM UTC
CRH Announces Share Buyback Program of Up to $6 Billion
CRH announced a new share buyback program of up to $6 billion, expiring at the end of 2030.
M impact | EQUITY | Oct 29, 2026, 10:05 AM UTC